Prevention CfDCa. HIV Surveillance Report, 2020. 2022 [cited 2022 July 19th, 2022]; http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
Alpren C, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs—Massachusetts, 2015–2018. Am J Public Health. 2020;110(1):37–44.
Golden MR, et al. Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs—Seattle, Washington, 2018. Morb Mortal Wkly Rep. 2019;68(15):344.
Hershow RB, et al. Notes from the field: HIV outbreak during the COVID-19 pandemic among persons who inject drugs—Kanawha County, West Virginia, 2019–2021. Morb Mortal Wkly Rep. 2022;71(2):66.
Lyss SB, et al. Responding to outbreaks of human immunodeficiency virus among persons who inject drugs—United States, 2016–2019: perspectives on recent experience and lessons learned. J Infect Dis. 2020;222(Supplement_5):S239–49.
Tookes H, et al. Rapid identification and investigation of an HIV risk network among people who inject drugs-Miami, FL. AIDS Behav. 2018;2019:1–11.
Peters PJ, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–39.
Fauci AS, et al. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–5.
Broz D, et al. Syringe services programs’ role in ending the HIV epidemic in the US: why we cannot do it without them. Am J Prev Med. 2021;61(5):S118–29.
Des Jarlais DC, et al. Expansion of syringe service programs in the United States, 2015–2018. Am J Public Health. 2020;110(4):517–9.
Sullivan PS, et al. Implementation strategies to increase PrEP uptake in the South. Curr HIV/AIDS Rep. 2019;16(4):259–69.
Bartholomew TS, et al. Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL. Harm Reduct J. 2020;17(1):1–8.
Tookes H, et al. Rapid identification and investigation of an HIV risk network among people who inject drugs-Miami, FL, 2018. AIDS Behav. 2020;24(1):246–56.
Kariisa M, et al. Drug overdose deaths involving cocaine and psychostimulants with abuse potential—United States, 2003–2017. Morb Mortal Wkly Rep. 2019;68(17):388.
Wilson N. Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR. 2020;69:290.
Spencer M, et al. Drug overdose deaths involving fentanyl, 2011–2016. Natl Vital Stat Rep. 2019;68:1–19.
Fogger SA. Methamphetamine use: a new wave in the opioid crisis? J Addict Nurs. 2019;30(3):219–23.
Palamar JJ, Han BH, Keyes KM. Trends in characteristics of individuals who use methamphetamine in the United States, 2015–2018. Drug Alcohol Depend. 2020;213:108089.
Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14–20.
Bradley H, et al. Estimated number of people who inject drugs in the United States. Clin Infect Dis. 2022. https://doi.org/10.1093/cid/ciac543.
CDC. 12 month-ending provisional number of drug overdose deaths. 2021 [cited 2021 October 22nd]; https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
Bartholomew TS, et al. Syringe Services Program (SSP) operational changes during the COVID-19 global outbreak. Int J Drug Policy. 2020;83:102821.
Glick SN, et al. The impact of COVID-19 on syringe services programs in the United States. AIDS Behav. 2020;24:2466–8.
Barocas JA, et al. Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;75:e1112–9.
Kaufman HW, et al. Decreases in hepatitis C testing and treatment during the COVID-19 pandemic. Am J Prev Med. 2021;61(3):369–76.
Wingrove C, et al. The impact of COVID-19 on hepatitis elimination. Lancet Gastroenterol Hepatol. 2020;5(9):792–4.
Jacka BP, et al. Impacts of the COVID-19 pandemic on healthcare access among patients receiving medication for opioid use disorder. Drug Alcohol Depend. 2021;221:108617.
Linas BP, et al. A clash of epidemics: impact of the COVID-19 pandemic response on opioid overdose. J Subst Abuse Treat. 2021;120:108158.
Aponte-Melendez Y, et al. The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services. Harm Reduct J. 2021;18(1):1–12.
Gleason E, et al. Barriers to care experienced by patients who inject drugs during the COVID-19 pandemic: a qualitative analysis. J Addict Med. 2021;16:e133–6.
Choopanya K, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–90.
Martin M, et al. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study. Lancet HIV. 2017;4(2):e59–66.
Escudero DJ, et al. Acceptability of HIV pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID) in a Canadian setting. AIDS Behav. 2015;19(5):752–7.
Mistler CB, Copenhaver MM, Shrestha R. The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review. AIDS Behav. 2021;25(5):1490–506.
Li DH, et al. Determinants of implementation for HIV pre-exposure prophylaxis based on an updated consolidated framework for implementation research: a systematic review. JAIDS. 2022;90(1):S235–46.
Biello K, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55.
Fanucchi L, Springer SA, Korthuis PT. Medications for treatment of opioid use disorder among persons living with HIV. Curr HIV/AIDS Rep. 2019;16(1):1–6.
Roux P, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49(9):1433–40.
Altice FL, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22.
Evans E, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006–10. Addiction. 2015;110(6):996–1005.
Nosyk B, et al. The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among HIV-positive people who inject drugs. Clin Infect Dis. 2015;61(7):1157–65.
Elkader A, Sproule B. Buprenorphine. Clin Pharmacokinet. 2005;44(7):661–80.
Lagisetty PA, et al. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76:979.
James K, Jordan A. The opioid crisis in black communities. J Law Med Ethics. 2018;46(2):404–21.
Larochelle MR, et al. Disparities in opioid overdose death trends by race/ethnicity, 2018–2019, from the HEALing communities study. Am J Public Health. 2021;111(10):1851–4.
Mason M, et al. Disparities by sex and race and ethnicity in death rates due to opioid overdose among adults 55 years or older, 1999 to 2019. JAMA Netw Open. 2022;5(1):e2142982–e2142982.
Santo T, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979–93.
Hansen H, et al. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14–21.
Kilaru AS, et al. Incidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients. JAMA Netw Open. 2020;3(5):e205852–e205852.
Goedel WC, et al. Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020;3(4):e203711–e203711.
Hansen HB, et al. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40(3):367–77.
Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016;160:82–9.
Andraka-Christou B. Addressing racial and ethnic disparities in the use of medications for opioid use disorder: study examines racial and ethnic disparities in the use of medications for opioid use disorder. Health Aff. 2021;40(6):920–7.
Hall G, et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J Subst Abuse Treat. 2014;46(4):511–5.
Iyengar S, et al. Baseline differences in characteristics and risk behaviors among people who inject drugs by syringe exchange program modality: an analysis of the Miami IDEA syringe exchange. Harm Reduct J. 2019;16(1):7.
Harris PA, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
Neale J. Iterative categorization (IC): a systematic technique for analysing qualitative data. Addiction. 2016;111(6):1096–106.
Salmona, M., Lieber, E., & Kaczynski, D. (2019). Qualitative and mixed methods data analysis using Dedoose: A practical approach for research across the social sciences. Sage Publications.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.
Rehm J, Probst C. Decreases of life expectancy despite decreases in non-communicable disease mortality: the role of substance use and socioeconomic status. Eur Addict Res. 2018;24(2):53–9.
Nambiar D, et al. Mortality and cause of death in a cohort of people who had ever injected drugs in Glasgow: 1982–2012. Drug Alcohol Depend. 2015;147:215–21.
Hser YI, et al. Mortality among substance-using mothers in California: a 10-year prospective study. Addiction. 2012;107(1):215–22.
Rehm J, et al. Trends in substance use and in the attributable burden of disease and mortality in the WHO European region, 2010–16. Eur J Pub Health. 2019;29(4):723–8.
Chang C-K, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry. 2010;10(1):1–7.
Lindblad R, et al. Mortality rates among substance use disorder participants in clinical trials: pooled analysis of twenty-two clinical trials within the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2016;70:73–80.
Iturralde E, et al. Premature mortality associated with severe mental illness or substance use disorder in an integrated health care system. Gen Hosp Psychiatry. 2021;68:1–6.
Gupta, A., Arman Qamar MDa, A. F., & Hainer, J. (2018). Cocaine and Marijuana Use among Young Adults Presenting with Myocardial Infarction: The Partners YOUNG-MI Registry.
Degenhardt L, et al. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend. 2011;113(2–3):88–95.
Motavalli D, et al. “Health is on the back burner:” multilevel barriers and facilitators to primary care among people who inject drugs. J Gen Intern Med. 2021;36(1):129–37.
McNeil R, et al. Hospitals as a ‘risk environment’: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014;105:59–66.
Muncan B, et al. “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):1–9.
Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: Health services experiences among people who inject drugs. International Journal of Drug Policy. 2018;57:104–10.
Spielberg F, et al. Overcoming barriers to HIV testing: preferences for new strategies among clients of a needle exchange, a sexually transmitted disease clinic, and sex venues for men who have sex with men. JAIDS-HAGERSTOWN MD-. 2003;32(3):318–27.
Strathdee SA, et al. Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health. 1999;76(4):448–60.
Strathdee SA, et al. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225–32.
Altice FL, et al. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health. 2003;80(3):416–27.
Schulkind J, et al. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepatitis. 2019;26(5):519–28.
Bachhuber MA, et al. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abuse. 2018;39(2):167–72.
Roth AM, et al. Integrating HIV preexposure prophylaxis with community-based syringe services for women who inject drugs: results from the Project SHE Demonstration Study. JAIDS. 2021;86(3):e61–70.
Ashford RD, Curtis B, Brown AM. Peer-delivered harm reduction and recovery support services: initial evaluation from a hybrid recovery community drop-in center and syringe exchange program. Harm Reduct J. 2018;15(1):52.
Wang CM. Offering community-based wound care as part of a comprehensive syringe exchange program. Honolulu: University of Hawai’i at Manoa; 2017.
Prevention CfDCa. HIV infection risk, prevention, and testing behaviors among persons who inject drugs—National HIV Behavioral Surveillance: injection drug use, 23 U.S. Cities, 2018. HIV surveillance special report 24. 2020 [cited 2022 June 17th]; https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
Streed CG, et al. Prevalence of HIV preexposure prophylaxis prescribing among persons with commercial insurance and likely injection drug use. JAMA Netw Open. 2022;5(7):e2221346–e2221346.
Sherman SG, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148–55.
McFarland W, et al. Low PrEP awareness and use among people who inject drugs, San Francisco, 2018. AIDS Behav. 2020;24(5):1290–3.
Jo Y, et al. Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida. PLoS ONE. 2020;15(4):e0231424.
Bazzi AR, et al. Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDS. 2018;32(12):529–37.
Roth AM, et al. An exploration of factors impacting preexposure prophylaxis eligibility and access among syringe exchange users. Sex Transm Dis. 2018;45(4):217–21.
Sivakumar A, et al. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: the potential role of telehealth, medications for opioid use disorder and minimal demands on patients. Int J Drug Policy. 2022;101:103570.
Harris R, et al. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program. Drug Alcohol Depend. 2022;230:109187.
Wang L, et al. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. J Subst Abuse Treat. 2021;124:108272.
Miller WC, et al. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. The Lancet. 2018;392(10149):747–59.
Sullivan LE, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006;43(Supplement_4):S184–90.
Lucas GM, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med. 2010;152(11):704–11.